CV Sciences (OTCMKTS:CVSI) Vs. HTBX, GRTX, ORPH, LTRN, LUMO, OSMT, AKTX, EVFM, RZLT, and MACK
Should you be buying CV Sciences stock or one of its competitors? The main competitors of CV Sciences include Heat Biologics (HTBX), Galera Therapeutics (GRTX), Orphazyme A/S (ORPH), Lantern Pharma (LTRN), Lumos Pharma (LUMO), Osmotica Pharmaceuticals (OSMT), Akari Therapeutics (AKTX), Evofem Biosciences (EVFM), Rezolute (RZLT), and Merrimack Pharmaceuticals (MACK). These companies are all part of the "pharmaceutical preparations" industry.
CV Sciences vs.
Galera Therapeutics (NASDAQ:GRTX) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Galera Therapeutics has a net margin of 0.00% compared to CV Sciences' net margin of -78.86%. Galera Therapeutics' return on equity of 0.00% beat CV Sciences' return on equity.
In the previous week, CV Sciences had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for CV Sciences and 0 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.00 equaled CV Sciences' average media sentiment score.
Galera Therapeutics presently has a consensus target price of $12.40, suggesting a potential upside of 360.97%. CV Sciences has a consensus target price of $0.42, suggesting a potential upside of 180.54%. Given Galera Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Galera Therapeutics is more favorable than CV Sciences.
CV Sciences received 171 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 66.56% of users gave CV Sciences an outperform vote while only 59.46% of users gave Galera Therapeutics an outperform vote.
CV Sciences has higher revenue and earnings than Galera Therapeutics. CV Sciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
76.2% of Galera Therapeutics shares are held by institutional investors. Comparatively, 0.0% of CV Sciences shares are held by institutional investors. 19.6% of Galera Therapeutics shares are held by company insiders. Comparatively, 6.8% of CV Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Galera Therapeutics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Summary
Galera Therapeutics beats CV Sciences on 9 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CVSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CV Sciences (OTCMKTS:CVSI) vs. Its Competitors
CV Sciences Competitors List
